Literature DB >> 34665346

Physical activity in idiopathic inflammatory myopathies: two intervention proposals based on literature review.

Rossella Talotta1, Irene Porrello2, Roberto Restuccia3, Ludovico Magaudda2,3.   

Abstract

Idiopathic inflammatory myopathies (IIM) are rare diseases affecting skeletal muscles and leading to progressive muscle weakness and disability. Thanks to the better understanding of their pathogenesis, the management of IIM has been noteworthily implemented in recent years. Current therapeutic strategies include pharmacological and non-pharmacological interventions, among which physical exercise represents a useful option, able to ameliorate disease activity without worsening muscle inflammation. The aim of this narrative review is therefore to provide an updated overview of the benefits of physical exercise in patients with IIM and to suggest plausible training programs to be applied in patients with dermatomyositis, polymyositis, necrotizing myopathy, and inclusion body myositis. In this regard, a combined strategy mixing aerobic and resistance exercises could positively affect the pro-inflammatory and metabolic pathways occurring in skeletal muscles, while promoting muscle fiber regeneration and repair.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Dermatomyositis; Exercise; Idiopathic inflammatory myopathies; Inclusion body myositis; Necrotizing myopathy; Physical activity; Polymyositis

Mesh:

Year:  2021        PMID: 34665346     DOI: 10.1007/s10067-021-05954-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  69 in total

Review 1.  Polymyositis and dermatomyositis (second of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-20       Impact factor: 91.245

Review 2.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

Review 3.  Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations.

Authors:  Floranne C Ernste; Ann M Reed
Journal:  Mayo Clin Proc       Date:  2013-01       Impact factor: 7.616

Review 4.  A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Authors:  Minoru Satoh; Shin Tanaka; Angela Ceribelli; S John Calise; Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 5.  Inflammatory muscle diseases: a critical review on pathogenesis and therapies.

Authors:  Marinos C Dalakas
Journal:  Curr Opin Pharmacol       Date:  2010-04-19       Impact factor: 5.547

6.  Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan.

Authors:  Daniel E Furst; Anthony A Amato; Şerban R Iorga; Kavita Gajria; Ancilla W Fernandes
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

Review 7.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 8.  Immune-Mediated Necrotizing Myopathy.

Authors:  Iago Pinal-Fernandez; Maria Casal-Dominguez; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2018-03-26       Impact factor: 4.592

9.  Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications.

Authors:  Marinos C Dalakas
Journal:  Acta Myol       Date:  2020-12-01

10.  2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Authors:  Ingrid E Lundberg; Anna Tjärnlund; Matteo Bottai; Victoria P Werth; Clarissa Pilkington; Marianne de Visser; Lars Alfredsson; Anthony A Amato; Richard J Barohn; Matthew H Liang; Jasvinder A Singh; Rohit Aggarwal; Snjolaug Arnardottir; Hector Chinoy; Robert G Cooper; Katalin Dankó; Mazen M Dimachkie; Brian M Feldman; Ignacio Garcia-De La Torre; Patrick Gordon; Taichi Hayashi; James D Katz; Hitoshi Kohsaka; Peter A Lachenbruch; Bianca A Lang; Yuhui Li; Chester V Oddis; Marzena Olesinska; Ann M Reed; Lidia Rutkowska-Sak; Helga Sanner; Albert Selva-O'Callaghan; Yeong-Wook Song; Jiri Vencovsky; Steven R Ytterberg; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2017-10-27       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.